Investigation of diarrhea and Clostridium difficile-colitis after lung cancer chemotherapy

Investigation of diarrhea and Clostridium difficile-colitis after lung cancer chemotherapy - Lung cancer chemothrapy, diarrhea, and Clostridium difficile-colitis study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000008432

Enrollment

250

Registered

2012-07-29

Start date

2012-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: an age of at least 20 years histologically or cytologically confirmed lung cancer scheduled for chemotherapy of TS-1, CPT-11, or taxane-anticancer drugs an Eastern Corporative Oncology Group (ECOG) performance status of 3 or less without diarrhea a life expectancy of at least 3 months

Exclusion criteria

Exclusion criteria: ileus diarrhea for more than three times a day before the administration of the anticancer agent a history of Clostridium difficile infection in the 2 months before enrollment mental disorders require the administration of antipsychotic major complications interfere with the continuation of the treatment

Design outcomes

Primary

Measure	Time frame
The incidence of diarrhea and Clostridium difficile-colitis after lung cancer chemotherapy	—

Secondary

Measure	Time frame
a preventive effect of probiotics against Clostridium difficile-colitis after lung cancer chemotherapy an effect of treatment for Clostridium difficile-colitis after lung cancer chemotherapy	—

Countries

Japan

Contacts

Public ContactTakao Kobayashi

North Japan Lung Cancer Study Group Sendai Kousei Hospital

ktakao@cat-v.ne.jp81-22-222-6181

Outcome results